Since BET proteins, CDK7, CDK9, and HDACs, serve as actionable targets in many cancers addicted to CRC, combination of CRC-disrupting agents with either current treatment modalities or novel antitumor compounds may improve therapeutic response. This evidence concerns the gene CDK9 and colorectal carcinoma.